文献速递骨软组织肉瘤与黑色素瘤

地舒单抗治疗骨巨细胞瘤:多中心开放标签2期研究

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
PubMed 文献 · Lancet Oncol · 2019-11-06

该多中心开放标签2期研究纳入532例骨巨细胞瘤患者,评估地舒单抗120 mg每4周皮下注射的安全性和活性。最常见≥3级不良事件为低磷血症(5%)、颌骨坏死(3%)。队列1中位进展或复发时间未达到,队列2中92%患者前6个月未手术。结论认为地舒单抗风险获益比仍有利。

要点

  • 地舒单抗常见≥3级不良事件为低磷血症5%、颌骨坏死3%。
  • 不可手术队列中位进展或复发时间未达到,11%发生进展或复发。
  • 可手术队列中92%患者前6个月未手术(95%CI 87-95)。

核心结论

  • 地舒单抗不良事件类型和频率与已知安全性一致,对不可切除和可切除骨巨细胞瘤均显示长期疾病控制。
  • 研究者认为地舒单抗治疗骨巨细胞瘤的总体风险获益比仍有利。

研究设计与样本

  • 多中心、开放标签、2期研究,在12个国家30个中心开展。
  • 纳入≥12岁、体重≥45 kg、组织学确诊且影像学可测量的骨巨细胞瘤患者。
  • 共532例患者入组:队列1(不可手术)267例,队列2(可手术但预计严重致残)253例,队列3(既往研究入组)12例。
  • 治疗方案为地舒单抗120 mg皮下注射每4周一次,队列1和2在第8天和第15天给予负荷剂量。
  • 主要终点为不良事件类型、频率和严重程度的安全性;次要终点包括队列1至疾病进展时间和队列2第6个月未手术比例。

主要发现

  • 治疗期最常见≥3级不良事件:低磷血症24例(5%)、颌骨坏死17例(3%)、肢体疼痛12例(2%)、贫血11例(2%)。
  • 严重不良事件138例(26%),最常见为颌骨坏死17例(3%)、贫血6例(1%)、骨巨细胞瘤6例(1%)、背痛5例(1%)。
  • 28例(5%)发生经 adjudication 的颌骨坏死,4例(1%)非典型股骨骨折,4例(1%)地舒单抗停药后30天发生高钙血症。
  • 队列1首次治疗期中位进展或复发时间未达到,262例中28例(11%)发生进展或复发。

临床怎么用

  • 地舒单抗可用于不可手术或手术可能导致严重致残的骨巨细胞瘤患者,需监测低磷血症和颌骨坏死等不良事件。

局限性

  • 本研究为单臂开放标签设计,无对照组的直接比较。
  • 随访时间及数据截止时部分终点尚未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of denosumab in patients with surgically salvageable or unsalvageable GCTB. METHODS: In this multicentre, open-label, phase 2 study done at 30 sites in 12 countries we enrolled adults and skeletally mature adolescents (aged ≥12 years) weighing at least 45 kg with histologically confirmed and radiographically measurable GCTB, Karnofsky performance status 50% or higher (Eastern Cooperative Oncology Group status 0, 1, or 2), and measurable active disease within 1 year of study enrolment. Patients had surgically unsalvageable GCTB (cohort 1), had surgically salvageable GCTB with planned surgery expected to result in severe morbidity (cohort 2), or were enrolled from a previous study of denosumab for GCTB (cohort 3). Patients received 120 mg subcutaneous denosumab once every 4 weeks during the treatment phase, with loading doses (120 mg subcutaneously) administered on study days 8 and 15 to patients in cohorts 1 and 2 (patients in cohort 3 did not receive loading doses). The primary endpoint was safety in terms of the type, frequency, and severity of adverse events; secondary endpoints included time to disease progression from cohort 1 and the proportion of patients without surgery at month 6 for cohort 2. The safety analysis set included all enrolled patients who received at least one dose of denosumab. This study is registered with ClinicalTrials.gov, number NCT00680992, and has been completed. FINDINGS: Between Sept 9, 2008, and Feb 25, 2016, 532 patients were enrolled: 267 in cohort 1, 253 in cohort 2, and 12 in cohort 3. At data cutoff on Feb 24, 2017, median follow-up was 58·1 months (IQR 34·0-74·4) in the overall patient population, and 65·8 months (40·9-82·4) in cohort 1, 53·4 months (28·2-64·1) in cohort 2, and 76·4 months (61·2-76·5) in cohort 3. During the treatment phase, the most common grade 3 or worse adverse events were hypophosphataemia (24 [5%] of 526 patients), osteonecrosis of the jaw (17 [3%], pain in extremity (12 [2%]), and anaemia (11 [2%]). Serious adverse events were reported in 138 (26%) of 526 patients; the most common were osteonecrosis of the jaw (17 [3%]), anaemia (6 [1%]), bone giant cell tumour (6 [1%]), and back pain (5 [1%]). 28 (5%) patients had positively adjudicated osteonecrosis of the jaw, four (1%) had atypical femur fracture, and four (1%) had hypercalcaemia occurring 30 days after denosumab discontinuation. There were four cases (1%) of sarcomatous transformation, consistent with historical data. Ten (2%) treatment-emergent deaths occurred (two of which were considered treatment-related; bone sarcoma in cohort 2 and sarcoma in cohort 1). Median time to progression or recurrence for patients in cohort 1 during the first treatment phase was not reached (28 [11%] of 262 patients had progression or recurrence). 227 (92%; 95% CI 87-95) of 248 patients who received at least one dose of denosumab in cohort 2 had no surgery in the first 6 months of the study. INTERPRETATION: The types and frequencies of adverse events were consistent with the known safety profile of denosumab, which showed long-term disease control for patients with GCTB with unresectable and resectable tumours. Our results suggest that the overall risk to benefit ratio for denosumab treatment in patients with GCTB remains favourable. FUNDING: Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019. PMID: 31704134. doi:10.1016/S1470-2045(19)30663-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。